The molecular interplay between USP32 and ERP44 in driving multiple myeloma progression and tumor growth. (PubMed, Cell Signal) - Sep 25, 2026 - "Notably, the PI3K-AKT inhibitor LY294002 significantly attenuated the proliferative advantage conferred by ERP44 overexpression, suggesting this pathway as a critical downstream effector. Furthermore, ERP44 overexpression upregulated UPR markers (GRP78, XBP1, and CHOP) as well as osteolytic factors (DKK1, RANKL, and MIP-1α), indicating its broader role in UPR and bone destruction. Collectively, these findings identify ERP44 as a pro-proliferative factor in MM and establish a USP32-ERP44-PI3K-AKT regulatory axis."
Journal • Hematological Malignancies • Multiple Myeloma • Oncology • Targeted Protein Degradation • CCND1 • CDK2 • DKK1 • HSPA5 • USP32 • XBP1
|
|
Guibo Ma; Hongjia Wang; Jiayue Sun; Yujuan Gao
|